Systemic Corticosteroids as an Adjunct Therapy in Pediatric Orbital Cellulitis: A Comprehensive Review and Meta-Analysis
-
By
-
Emily S. Acker
-
Gabriela Martin Gonzalez
-
Dylan Davie
-
Ratna B. Basak
-
April 20, 2026
Clinical Scorecard: Systemic Corticosteroids as an Adjunct Therapy in Pediatric Orbital Cellulitis: A Comprehensive Review and Meta-Analysis
At a Glance
| Category | Detail |
|---|
| Condition | |
| Key Mechanisms | Adjunctive systemic corticosteroids may reduce inflammation but carry risks of worsening infection and adverse outcomes. |
| Target Population | |
| Care Setting | |
Key Highlights
- Corticosteroids did not significantly reduce hospital length of stay.
- Increased risks of surgical intervention and PICU admission associated with corticosteroid use.
- Higher rates of 30-day readmission observed in corticosteroid group.
- Evidence quality was low to moderate due to observational study designs.
- Need for high-quality randomized controlled trials to clarify corticosteroid role and address gaps in evidence.
Guideline-Based Recommendations
Diagnosis
Management
Monitoring & Follow-up
Risks
- Be aware of potential increased risks associated with corticosteroid use, including surgical intervention and readmission.
- Further research is needed to clarify the role of corticosteroids in pediatric orbital cellulitis.
Patient & Prescribing Data
Pediatric patients under 21 years with orbital cellulitis
Corticosteroids may not provide clinical benefits and could increase adverse outcomes.
Clinical Best Practices
- Consider the risks versus benefits of corticosteroid use in pediatric orbital cellulitis.
- Adhere to evidence-based guidelines for antibiotic therapy.
- Ensure close monitoring of patients for complications during hospitalization.
- Encourage interdisciplinary collaboration in managing pediatric patients with orbital cellulitis.
Related Resources & Content
